Bio-Path Holdings, Inc. (NASDAQ:BPTH) Expected to Post Earnings of -$0.32 Per Share

Analysts expect that Bio-Path Holdings, Inc. (NASDAQ:BPTH) will post earnings per share (EPS) of ($0.32) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Bio-Path’s earnings. The lowest EPS estimate is ($0.35) and the highest is ($0.29). Bio-Path posted earnings per share of ($0.57) during the same quarter last year, which would indicate a positive year-over-year growth rate of 43.9%. The company is expected to announce its next earnings report on Wednesday, March 9th.

On average, analysts expect that Bio-Path will report full-year earnings of ($1.28) per share for the current year, with EPS estimates ranging from ($1.31) to ($1.25). For the next financial year, analysts expect that the business will post earnings of ($1.40) per share, with EPS estimates ranging from ($1.40) to ($1.39). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that that provide coverage for Bio-Path.

Bio-Path (NASDAQ:BPTH) last posted its earnings results on Friday, November 12th. The company reported ($0.29) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.33) by $0.04. During the same quarter in the prior year, the business posted ($0.80) EPS.

A number of analysts recently weighed in on BPTH shares. Zacks Investment Research raised shares of Bio-Path from a “hold” rating to a “buy” rating and set a $4.25 target price on the stock in a report on Wednesday. HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of Bio-Path in a report on Monday, November 15th.

Bio-Path stock opened at $3.94 on Friday. The firm’s 50 day simple moving average is $4.28 and its 200 day simple moving average is $5.23. The firm has a market capitalization of $28.24 million, a PE ratio of -2.54 and a beta of 1.65. Bio-Path has a 1-year low of $3.72 and a 1-year high of $24.34.

Several large investors have recently modified their holdings of BPTH. Morgan Stanley boosted its position in Bio-Path by 1,525.4% during the 3rd quarter. Morgan Stanley now owns 21,130 shares of the company’s stock valued at $108,000 after buying an additional 19,830 shares during the period. Citadel Advisors LLC boosted its position in Bio-Path by 23.1% during the 2nd quarter. Citadel Advisors LLC now owns 25,356 shares of the company’s stock valued at $169,000 after buying an additional 4,765 shares during the period. State Street Corp purchased a new stake in Bio-Path during the 2nd quarter valued at $81,000. Northern Trust Corp purchased a new stake in Bio-Path during the 2nd quarter valued at $119,000. Finally, Geode Capital Management LLC boosted its position in Bio-Path by 15.5% during the 2nd quarter. Geode Capital Management LLC now owns 65,353 shares of the company’s stock valued at $435,000 after buying an additional 8,763 shares during the period. 6.06% of the stock is currently owned by hedge funds and other institutional investors.

About Bio-Path

Bio-Path Holdings, Inc is a biotechnology company, which engages in the develpment of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline include Prexigebersen, BP1002, and BP1003. The company was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.

Recommended Story: Breakout Stocks

Get a free copy of the Zacks research report on Bio-Path (BPTH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.